Theodoulidis, V.; Kissoudi, K.; Chatzistamatiou, K.; Tzitzis, P.; Zouzoulas, D.; Theodoulidis, I.; Anthoulakis, C.; Moysiadis, T.; Topalidou, M.; Timotheadou, E.;
et al. Neutrophil–Lymphocyte Ratio and KELIM Score as Prognostic Markers in High-Grade Serous Advanced Ovarian Cancer Patients Treated with Neoadjuvant Chemotherapy. Biomedicines 2025, 13, 975.
https://doi.org/10.3390/biomedicines13040975
AMA Style
Theodoulidis V, Kissoudi K, Chatzistamatiou K, Tzitzis P, Zouzoulas D, Theodoulidis I, Anthoulakis C, Moysiadis T, Topalidou M, Timotheadou E,
et al. Neutrophil–Lymphocyte Ratio and KELIM Score as Prognostic Markers in High-Grade Serous Advanced Ovarian Cancer Patients Treated with Neoadjuvant Chemotherapy. Biomedicines. 2025; 13(4):975.
https://doi.org/10.3390/biomedicines13040975
Chicago/Turabian Style
Theodoulidis, Vasilis, Kalliopi Kissoudi, Kimon Chatzistamatiou, Panagiotis Tzitzis, Dimitris Zouzoulas, Iakovos Theodoulidis, Christos Anthoulakis, Theodoros Moysiadis, Maria Topalidou, Eleni Timotheadou,
and et al. 2025. "Neutrophil–Lymphocyte Ratio and KELIM Score as Prognostic Markers in High-Grade Serous Advanced Ovarian Cancer Patients Treated with Neoadjuvant Chemotherapy" Biomedicines 13, no. 4: 975.
https://doi.org/10.3390/biomedicines13040975
APA Style
Theodoulidis, V., Kissoudi, K., Chatzistamatiou, K., Tzitzis, P., Zouzoulas, D., Theodoulidis, I., Anthoulakis, C., Moysiadis, T., Topalidou, M., Timotheadou, E., Grimpizis, G., & Tsolakidis, D.
(2025). Neutrophil–Lymphocyte Ratio and KELIM Score as Prognostic Markers in High-Grade Serous Advanced Ovarian Cancer Patients Treated with Neoadjuvant Chemotherapy. Biomedicines, 13(4), 975.
https://doi.org/10.3390/biomedicines13040975
